Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced positive top-line data in an open-label Phase I/II extension clinical trial of the investigational T-cell vaccine, Tovaxin(TM), for multiple sclerosis (MS). In this one-year, 8-subject extension clinical trial of relapsing remitting (RRMS) and secondary progressive (SPMS) subjects, Tovaxin therapy was shown to be safe and effective. The "per-protocol" analysis of Tovaxin therapy achieved a 92% reduction in annualized relapse rate (ARR) in subjects who received two treatment doses of 30 - 45 x 10(6) attenuated T-cells eight weeks apart and were monitored for an additional 44 weeks. Subjects in the extension study had previously been treated an average of 5.2+/-1.8 (1, 8; median 5.4) years earlier at Baylor College of Medicine under the direction of Jingwu Zhang, M.D., Ph.D with a T-cell vaccine developed from myelin basic protein (MBP) reactive T-cells. The safety profile revealed only injection site mild reactions and no severe adverse reactions related to T-cell vaccination.

Both Phase I/II clinical studies have demonstrated that T-cell vaccination depletes myelin reactive T-cells in peripheral blood. In the extension study patient population, the myelin reactive T-cell frequencies were reduced by 84% and 72% at 6 and 12 months on study, respectively. Reductions in myelin reactive T-cell frequencies in the dose escalation study were 76.7% and 64.8% at 6 and 12 months on study, respectively.

All subjects currently are enrolled in a retreatment extension study to collect longitudinal safety and effectiveness data.

Effectiveness data for the 13 RRMS subjects across the two Phase I/II trials showed an 80% reduction in ARR. The Expanded Disability Scoring Scale (EDSS) for the RRMS subjects for a 0.5 point effect was
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:10/20/2014)... Oct. 20, 2014  AnaptysBio, Inc., a leader ... today announced the appointment of Marco Londei ... will lead the preclinical and clinical development of ... are pleased to welcome Dr. Londei to AnaptysBio,s ... President and Chief Executive Officer of AnaptysBio. "Dr. ...
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/19/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Wednesday, October 29, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Wednesday, October 29 1:30 ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... a blood test improve,treatment outcomes for colorectal cancer ... management --,measuring drug levels in patients, blood and ... severe toxicity and improve efficacy in,colorectal cancer., ... cancer patients, by,Erick Gamelin, M.D., Ph.D. et. al., ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... Association annual meeting the results of,a Phase 2a ... of acute agitation in schizophrenic patients. The poster,presentation, ... (Presentation NR5-032), will be available for,viewing at the ...
Cached Medicine Technology:Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 2Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 3Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 4Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 5Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting 2
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... and is performed without anesthesia , , WEDNESDAY, Oct. 3 ... of an innovative form of colonoscopy that relies on ... , When it comes to detecting polyps that ... as effective as the traditional approach of using a ...
... It cuts rates of hospitalizations and deaths, study finds, , , WEDNESDAY, ... an annual flu shot will reduce the risk you,ll be hospitalized ... flu-related death by 48 percent. , That,s the conclusion of new ... England Journal of Medicine . , "This is a bad disease ...
... Calif., Oct. 3 Abaxis, Inc.,(Nasdaq: ABAX ... analysis systems, announced today the launch of the ... the Piccolo xpress(TM) point of,care analyzer. The ... imaging and,radiology centers in the United States to ...
... Acceptance of Umbilical Cord Blood Stem Cells as a Curative ... ... Inc. has been named,to Deloitte,s prestigious Technology Fast 50 Program for ... life sciences companies in the area by Deloitte & Touche USA ...
... CHICAGO, Oct. 3 President Bush,s veto today,of ... for millions of,children from families with low incomes ... dental health, says Oral Health America, a national,advocacy ... ten million children eligible for coverage through a,bipartisan, ...
... regarded as a barometer of a populations general health ... rate in 2006 was 5.9 infant deaths for every 1,000 ... made major progress in reducing infant deaths since the early ... but the decline has leveled off in recent years. The ...
Cached Medicine News:Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3Health News:Flu Vaccine Does Protect Older People 2Health News:Flu Vaccine Does Protect Older People 3Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 2Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 4Health News:SCHIP Veto a Big Cavity for Children's Oral Healthcare, Advocates Say 2Health News:New York City's infant mortality rate declined in 2006 2Health News:New York City's infant mortality rate declined in 2006 3Health News:New York City's infant mortality rate declined in 2006 4
... The Aisys Carestation helps you deliver unmatched ... Aisys Carestation is the most complete anesthesia ... point of need - at your fingertips., ... our industry-leading Datex-Ohmeda legacy of anesthesia delivery ...
... Mesh LP is a super-light polypropylene mesh ... body reaction is reduced considerably. Optilene Mesh ... all open hernia repair procedures. It perfectly ... flexibility Optilene Mesh LP adapts to the ...
... Optilene Mesh Elastic is a lightweight and ... elasticity the mesh is able to adapt to ... The new honeycomb like structure with the large ... elastic scar. The mesh is ideal for incisional ...
... LP is a lightweight polypropylene mesh ... considerably reduced,foreign body reaction. The softer, ... It perfectly conforms to,anatomical structures. Due ... LP adapts to the movements of ...
Medicine Products: